Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL

For patients with heavily pretreated multiple myeloma, responses seen with the novel chimeric antigen receptor T-cell (CAR T-cell) construct ciltacabtagene autoleucel have also been durable.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news